cdifffoundation.org
First Patient Is Enrolled In Rebiotix Phase 3 Clinical Trial of RBX2660 For the Prevention of Recurrent C. difficile Infection
REBIOTIX Phase 3 Clinical Trial of RBX2660 for the Prevention of Recurrent Clostridium difficile Infection Phase 3 Initiation Advances Development of Lead Microbiome-based Drug, RBX2660, Fol…